Phaseline

Companies › Theravance Biopharma

Theravance Biopharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Cardiovascular; next expected readout Jan 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Ampreloxetine
Norepinephrine transporter inhibitor
SLC6A2Phase 3Symptomatic Neurogenic Orthostatic HypotensionJan 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05696717AmpreloxetinePhase 3Symptomatic Neurogenic Orthostatic HypotensionCardiovascularJan 2028

From the company's SEC filings

Cash and short-term investments of $388m on 2026-06-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

SLC6A2 (1)

Companies with the same targets

Axsome Therapeutics Supernus Pharmaceuticals Currax Pharmaceuticals Otsuka Resilient Pharmaceuticals Remedy Definium Therapeutics US

Companies built like this

Boston Scientific Inhibikase Therapeutics Kiniksa Pharmaceuticals International CeleCor Therapeutics MedTrace Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.